Generic drugmaker to pay $3m antitrust fine

New Jersey-based generic drugmaker Rising Pharmaceuticals has admitted to conspiring to fix prices and allocate customers for a generic hypertension drug.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Americas

Allergan pays $750m to resolve antitrust litigation

29 October 2019 Allergan has reached a $750 million deal to resolve antitrust litigation brought against its subsidiary Forest Laboratories over Alzheimer’s drug Namenda.

Americas

Amneal and others pay $1.5m to settle antitrust suit over Alzheimer’s drug

20 August 2019 Amneal and three other generic makers have agreed to pay $1.54 million to settle a class-action lawsuit, which alleged the companies engaged in an unlawful scheme to maintain their monopoly over an Alzheimer’s drug.

More on this story

Americas

Allergan pays $750m to resolve antitrust litigation

29 October 2019 Allergan has reached a $750 million deal to resolve antitrust litigation brought against its subsidiary Forest Laboratories over Alzheimer’s drug Namenda.

Americas

Amneal and others pay $1.5m to settle antitrust suit over Alzheimer’s drug

More on this story

Americas

Allergan pays $750m to resolve antitrust litigation

29 October 2019 Allergan has reached a $750 million deal to resolve antitrust litigation brought against its subsidiary Forest Laboratories over Alzheimer’s drug Namenda.

Americas

Amneal and others pay $1.5m to settle antitrust suit over Alzheimer’s drug